FLUCTUATION OF SALIVA PLASMA-CONCENTRATION RATIO AND SALIVARY CLEARANCE OF 5-FLUOROURACIL FOLLOWING BOLUS INTRAVENOUS ADMINISTRATION IN RATS

被引：0
|
作者：
HAYASHI, Y
WATANABE, J
OZEKI, S
IWAMOTO, K
机构：
[1] NAGOYA CITY UNIV,FAC PHARMACEUT SCI,NAGOYA,AICHI 467,JAPAN
[2] SHIMANE MED UNIV HOSP,DEPT PHARM,IZUMO,JAPAN
来源：
JOURNAL OF PHARMACEUTICAL SCIENCES | 1987年 / 76卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
引用
收藏
页码：S73 / S73
页数：1
相关论文
共 35 条
  • [21] CIRCADIAN RHYTHM-VARYING PLASMA-CONCENTRATION OF 5-FLUOROURACIL DURING A 5-DAY CONTINUOUS VENOUS INFUSION AT A CONSTANT RATE IN CANCER-PATIENTS
    PETIT, E
    MILANO, G
    LEVI, F
    THYSS, A
    BAILLEUL, F
    SCHNEIDER, M
    CANCER RESEARCH, 1988, 48 (06) : 1676 - 1679
  • [22] Plasma concentrations of 5-fluorouracil and F-β-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil
    Yamada, Y
    Hamaguchi, T
    Goto, M
    Muro, K
    Matsumura, Y
    Shimada, Y
    Shirao, K
    Nagayama, S
    BRITISH JOURNAL OF CANCER, 2003, 89 (05) : 816 - 820
  • [23] Plasma concentrations of 5-fluorouracil and F-β-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil
    Y Yamada
    T Hamaguchi
    M Goto
    K Muro
    Y Matsumura
    Y Shimada
    K Shirao
    S Nagayama
    British Journal of Cancer, 2003, 89 : 816 - 820
  • [24] PHARMACOKINETICS OF 5-FLUOROURACIL AFTER SHORT SYSTEMIC INFUSION - PLASMA-LEVEL AT THE END OF THE DISTRIBUTION PHASE AS AN INDICATOR OF THE TOTAL AREA UNDER THE PLASMA-CONCENTRATION TIME CURVE
    PORT, RE
    EDLER, L
    HERRMANN, R
    FELDMANN, U
    THERAPEUTIC DRUG MONITORING, 1991, 13 (02) : 96 - 102
  • [25] COMPARISON OF 5-FLUOROURACIL PHARMACOKINETICS FOLLOWING INTRAPERITONEAL AND INTRAVENOUS ADMINISTRATION USING INVIVO F-19 MAGNETIC-RESONANCE SPECTROSCOPY
    GLAHOLM, J
    LEACH, MO
    COLLINS, D
    ALJEHAZI, B
    SHARP, JC
    SMITH, TAD
    ADACH, J
    HIND, A
    MCCREADY, VR
    WHITE, H
    BRITISH JOURNAL OF RADIOLOGY, 1990, 63 (751): : 547 - 553
  • [26] Association between circadian and chemotherapeutic cycle effects on plasma concentration of 5-fluorouracil and the clinical outcome following definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in patients with esophageal squamous cell carcinoma
    Kuwahara, Akiko
    Kobuchi, Shinji
    Tamura, Takao
    ONCOLOGY LETTERS, 2019, 17 (01) : 668 - 675
  • [27] Plasma, intestine and tumor levels of 5-fluorouracil in mice bearing L1210 ascites tumor following oral administration of 5-fluorouracil, UFT (Mixed compound of tegafur and uracil), carmofur and 5′-deoxy-5-fluorouridine
    Ooi, K
    Ohkubo, T
    Higashigawa, M
    Kawasaki, H
    Kakito, H
    Kagawa, Y
    Kojima, M
    Sakurai, M
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2001, 24 (11) : 1329 - 1331
  • [28] Plasma concentration profile of tolterodine and 5-hydroxymethyl tolterodine following transdermal administration of tolterodine in rats
    Ji, Young Seok
    Kim, In Sook
    Kim, Tae Kon
    Yoo, Hye Hyun
    PHARMAZIE, 2018, 73 (07): : 375 - 378
  • [29] Plasma and salivary pharmacokinetics of 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer receiving 5-FU bolus plus continuous infusion with high-dose folinic acid
    Joulia, JM
    Pinguet, F
    Ychou, M
    Duffour, J
    Astre, C
    Bressolle, F
    EUROPEAN JOURNAL OF CANCER, 1999, 35 (02) : 296 - 301
  • [30] PHARMACOLOGY AND ANTITUMOR-ACTIVITY OF 5-FORMYLTETRAHYDROFOLATE (CF) ADMINISTERED BY DIFFERENT ROUTES IN COMBINATION WITH INTRAVENOUS ADMINISTRATION OF 5-FLUOROURACIL (FURA) TO RATS WITH COLON-CARCINOMA (CC)
    LIU, L
    RUSTUM, YM
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1988, 29 : 353 - 353
1234